Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. Chief Financial Officer James Budge reported an exempt share withholding tied to equity compensation. On 02/01/2026, 3,036 shares of Class A common stock were disposed of at $34.9 per share to cover tax obligations from vested restricted stock units under Section 16b-3(e).
All 3,036 shares were relinquished by the officer and cancelled by the company in exchange for the company paying his federal and state tax withholding liabilities. After this transaction, he beneficially owned 434,895 Class A common shares in direct form.
Jane Street Group, LLC and affiliated entities filed an amended Schedule 13G reporting a passive stake in Hinge Health, Inc. They report beneficial ownership of 1,588,611 shares of Class A common stock, representing 4.2% of the class, with shared voting and dispositive power over all reported shares.
The filing states the securities were not acquired and are not held to change or influence control of Hinge Health, indicating a passive investment position rather than an activist role.
The Vanguard Group reports beneficial ownership of 2,605,532 shares of Hinge Health Inc common stock, representing 6.87% of the class as of 12/31/2025.
Vanguard reports no sole voting or dispositive power, with shared voting power over 121,736 shares and shared dispositive power over 2,605,532 shares. The securities are held for Vanguard’s clients, who are entitled to dividends and sale proceeds, and no single other person has an interest over 5% of the class.
Vanguard certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Hinge Health. Vanguard also notes an internal realignment on January 12, 2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
Hinge Health, Inc. investor HANSAINVEST Hanseatische Investment-Limited Co reported beneficial ownership of 2,157,071 ordinary shares, representing 5.69% of the class as of December 31, 2025.
The shares are held for investment funds managed by HANSAINVEST, which under German law has sole voting and dispositive power. The position is certified as acquired and held in the ordinary course of business, not to change or influence control of Hinge Health.
Hinge Health, Inc. CEO, Co-Founder, director and 10% owner reported insider transactions dated 01/05/2026. The reporting person converted 166,665 shares of Class B Common Stock into 166,665 shares of Class A Common Stock at an exercise price of $0, then sold 122,368 Class A shares at a weighted average price of $46.2458 and a further 44,297 Class A shares at a weighted average price of $46.7664.
The sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025. Following these transactions, indirect holdings include 35,470 Class A shares held by a spouse, and derivative holdings include 14,376,762 shares of Class B Common Stock and 515,705 Class A shares through a spouse, each Class B share being convertible into one Class A share as described in the company’s charter.
A security holder of HNGE has filed a notice of proposed sale under Rule 144 for 166,665 shares of common stock, with an aggregate market value of $7,593,257.40. The filing lists Morgan Stanley Smith Barney LLC as broker, notes that 37,919,155 shares of this class were outstanding, and indicates an approximate sale date of January 5, 2026 on the NYSE.
The shares were acquired on March 22, 2023 through restricted stock awards from the issuer in the same amount. The document also reports prior Rule 10b5-1 sales for Daniel Perez of 166,670 shares of common stock on December 15, 2025 for gross proceeds of $8,088,311.76. By signing, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s operations.
Hinge Health, Inc. reported an insider equity transaction by its President on a Form 4. On 01/01/2026, the officer disposed of 1,118 shares of Class A common stock at $46.45 per share under transaction code F, which indicates shares withheld to cover taxes on vesting equity awards. After this tax-related share withholding, the reporting person beneficially owned 768,660 shares of Class A common stock, held directly. The filing notes that the shares relinquished were cancelled by the company in exchange for the company’s agreement to satisfy the officer’s federal and state tax withholding obligations arising from the vesting of restricted stock units.
Hinge Health, Inc. reported that its Chief Financial Officer disposed of Class A common stock in a routine tax-related transaction. On 01/01/2026, the CFO had 3,243 shares of Class A common stock withheld and cancelled at a value of $46.45 per share in an exempt transaction coded "F" under Section 16b-3(e). This means shares were surrendered to the company to cover federal and state tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market. Following this transaction, the CFO beneficially owned 437,931 shares of Class A common stock directly.
An officer of Hinge Health, Inc. reported selling 15,000 shares of the company’s Class A common stock on 12/22/2025. The shares were sold in an open-market transaction at a weighted average price of $48.3967, with individual sale prices ranging from $47.785 to $48.74.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to allow insiders to trade on a scheduled basis. After this transaction, the reporting person beneficially owns 769,778 shares of Hinge Health’s Class A common stock. The total in Table I also reflects a correction to the reported ownership previously shown in Forms 4 filed on November 24, 2025 and December 1, 2025.
Hinge Health, Inc. Chief Financial Officer James Budge reported selling 10,491 shares of Class A common stock on 12/22/2025 in an open-market transaction. The shares were sold at a weighted average price of $48.4069 per share, with individual sale prices ranging from $47.81 to $48.74. The transaction was executed under a Rule 10b5-1 trading plan that he adopted on June 12, 2025. Following this sale, Budge beneficially owns 441,174 shares of Hinge Health Class A common stock, held directly.